StemGenex Applauds Donald Trump’s Signing of ‘Right-to-Try’ Allowing Gravely Ill to Bypass FDA for Experimental MedicinesAugust 30, 2018
President Donald Trump has recently signed the “right-to-try” bill empowering gravely ill patients to bypass drug regulators and gain access to experimental medicines.
The legislation allows patients with life-threatening conditions to ask drugmakers for medicines that have cleared some testing but still haven’t been approved by the Food and Drug Administration. Previously, patients would need to ask the Food and Drug Administration (FDA) for access to experimental treatments.
Rita Alexander, Chief Administrative Officer at StemGenex in San Diego, CA, applauded Donald Trump and the signing of the “right-to-try” bill. She noted that over the past four years, “right-to-try” advocates in over 30 states have helped enact legislation to eliminate legal obstacles blocking terminally ill patients from treatments that aren’t yet approved by the FDA. Those advocates are showing considerable momentum in the remaining states, potentially upending the established order for experimental drugs.
“Now,” said Alexander, “the Federal government has joined the chorus and has provided a path for desperately ill patients to receive therapies that offer hope and healing.”
StemGenex is a stem cell therapy health center committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex uses adipose-derived autologous stem cell therapy for patients battling conditions such as Multiple Sclerosis, Parkinson’s Disease, COPD, Rheumatoid Arthritis and Osteoarthritis.
Trump and Vice President Mike Pence have been major supporters of passing the measure, which proponents say gives patients hope they would not otherwise have. Recently, the House of Representatives approved the bill, the same version the Senate passed in August 2017.
It allows certain patients to ask drugmakers for medicines that have passed Phase 1 of the FDA approval process but haven’t been approved yet and are still undergoing testing. Patients must have exhausted other options and be unable to participate in a clinical trial. Drugmakers aren’t obligated to give patients the requested experimental medicines.
“Right to try. That’s such a great name,” Trump said. “Some bills, they don’t have a good name. Really. But this is such a great name, from the first day I heard it. Right to try. And a lot of the trying is going to be successful. I really believe that. I really believe it.”
ABOUT StemGenex Stem Cell Research Centre
StemGenex Stem Cell Research is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides access to stem cell therapy for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment, StemGenex sponsors five clinical outcome studies registered with the National Institutes of Health (NIH) for Multiple Sclerosis, Parkinson’s Disease, Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD) and Osteoarthritis. These have been established to formally document and evaluate the quality of life changes in individuals following adipose-derived stem cell treatment.